|Generic Name||:||Omeprazole BP|
|Therapeutic Class||:||Anti-Ulcerant, PPI|
|Pack Size||:||10x6's; 5x4's|
Omeprazole is the first drug to be marketed in a group of agents which reduce gastric acid secretion by inhibition H+/K+ATPase (the 'proton pump') of the parietal cell. These agents are the most potent inhibitors of gastric acid secretlon.
Omaprazole is indicated where suppression of acid secretion is of therapeutic benefit. It may be used for short and long term therapy in -
i) Duodenal ulcer ii) Gastric ulcer iii) Reflux esophagitis and esophageal ulceration iv) Maintenance of healing of erosive esophagitis v) Pathological hypersecretory conditions (e.g. Zollinger-Ellison Syndrome, multiple endocrine adenomas and systemic mastocytosis) vi) Resistant peptic ulcer vii) Eradication of Helicobacter pylori in combination with suitable antibiotics.